HRP20230300T1 - Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije - Google Patents
Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije Download PDFInfo
- Publication number
- HRP20230300T1 HRP20230300T1 HRP20230300TT HRP20230300T HRP20230300T1 HR P20230300 T1 HRP20230300 T1 HR P20230300T1 HR P20230300T T HRP20230300T T HR P20230300TT HR P20230300 T HRP20230300 T HR P20230300T HR P20230300 T1 HRP20230300 T1 HR P20230300T1
- Authority
- HR
- Croatia
- Prior art keywords
- imetelstat
- abt
- use according
- combination
- sodium
- Prior art date
Links
- LQBVNQSMGBZMKD-UHFFFAOYSA-N venetoclax Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 title claims 25
- 229960001183 venetoclax Drugs 0.000 title claims 25
- LVZYXEALRXBLJZ-ISQYCPACSA-N f60ne4xb53 Chemical compound N1([C@@H]2O[C@@H]([C@H](C2)NP(O)(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP(S)(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)N[C@H]2C[C@@H](O[C@@H]2COP(O)(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O LVZYXEALRXBLJZ-ISQYCPACSA-N 0.000 title claims 22
- 229950004291 imetelstat Drugs 0.000 title claims 22
- 208000031261 Acute myeloid leukaemia Diseases 0.000 title claims 11
- IEVORMRANFJJFR-NMZIRJKDSA-A imetelstat sodium Chemical compound [Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].N1([C@@H]2O[C@@H]([C@H](C2)NP([O-])(=S)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)NP([S-])(=O)OC[C@@H]2[C@H](C[C@@H](O2)N2C3=NC=NC(N)=C3N=C2)N)COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)N[C@H]2C[C@@H](O[C@@H]2COP([O-])(=S)OCC(O)CNC(=O)CCCCCCCCCCCCCCC)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C(NC(=O)C(C)=C2)=O)N2C(NC(=O)C(C)=C2)=O)N2C3=NC=NC(N)=C3N=C2)N2C3=C(C(NC(N)=N3)=O)N=C2)N2C3=NC=NC(N)=C3N=C2)C=CC(N)=NC1=O IEVORMRANFJJFR-NMZIRJKDSA-A 0.000 claims 18
- 238000000034 method Methods 0.000 claims 9
- 238000001990 intravenous administration Methods 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 5
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Claims (21)
1. Imetelstat za uporabu u liječenju akutne mijeloidne leukemije (AML) kod pacijenata koji se liječe sa ABT-199 ili njegovom farmaceutski prihvatljivom soli.
2. ABT-199 ili njegova farmaceutski prihvatljiva sol za uporabu u liječenju akutne mijeloidne leukemije (AML) kod pacijenata koji su podvrgnuti liječenju imtelstatom.
3. Imetelstat za uporabu u postupku liječenja akutne mijeloidne leukemije (AML), pri čemu postupak obuhvaća davanje imetelstata i ABT-199 ili njegove farmaceutski prihvatljive soli u kombinaciji subjektu kojem je to potrebno.
4. Kombinacija koja sadrži imetelstat i ABT-199 ili njihovu farmaceutski prihvatljivu sol za uporabu u postupku liječenja akutne mijeloidne leukemije (AML), pri čemu postupak obuhvaća davanje kombinacije subjektu kojem je to potrebno.
5. Imetelstat za uporabu prema patentnim zahtjevima 1-3 ili kombinacija za uporabu prema patentnom zahtjevu 4, pri čemu je imetelstat natrij imetelstat.
6. Imetelstat za uporabu prema patentnim zahtjevima 1-3 ili kombinacija za uporabu prema patentnom zahtjevu 4, pri čemu se imetelstat primjenjuje za 1, 2, 3, 4, 5, 6, 7, 8 ili više od 8 ciklusa doziranja, pri čemu svaki ciklus doziranja sadrži:
(a) intravensku primjenu 7 - 10 mg/kg imetelstata jednom u četiri tjedna;
(b) intravensku primjenu 7 - 10 mg/kg imetelstata jednom tjedno tijekom četiri tjedna;
(c) intravensku primjenu 2.5 - 7 mg/kg imetelstata jednom u tri tjedna; ili
(d) intravensku primjenu 0.5 - 9.4 mg/kg imetelstata jednom u četiri tjedna.
7. Imetelstat za uporabu prema patentnom zahtjevu 6 ili kombinacija za uporabu prema zahtjevu 6, gdje je imetelstat natrij imetelstat.
8. Imetelstat za uporabu prema patentnim zahtjevima 1-3 ili kombinacija za uporabu prema patentnom zahtjevu 4, gdje je ABT-199 za primjenu u dozi od:
(a) 50 - 400 mg ABT-199 dnevno;
(b) 2 mg ABT-199 prvog dana sa dnevnom eskalacijom do konačne doze od 800 mg 6 dana i dnevno nakon toga; ili
(c) 25 mg ABT-199 prvog dana sa dnevnom eskalacijom do konačne doze od 400 mg 5 dana i dnevno nakon toga.
9. Imetelstat za uporabu prema patentnim zahtjevima 1-3 ili kombinacija za uporabu prema patentnom zahtjevu 4, pri čemu je primjena ABT-199 jedan dan prije, jedan dan poslije ili istog dana kada je primjena imetelstata.
10. Imetelstat natrij za uporabu u postupku liječenja akutne mijeloidne leukemije (AML) prema patentnom zahtjevu 3, pri čemu postupak obuhvaća davanje imetelstat natrija i ABT-199 u kombinaciji subjektu kojem je to potrebno.
11. ABT-199 za uporabu u postupku liječenja akutne mijeloidne leukemije (AML) prema patentnom zahtjevu 2, pri čemu postupak obuhvaća davanje ABT-199 i imetelstat natrija u kombinaciji subjektu kojem je to potrebno.
12. Kombinacija koja sadrži imetelstat natrij i ABT-199 za uporabu u postupku liječenja akutne mijeloidne leukemije (AML) prema patentnom zahtjevu 4, pri čemu postupak obuhvaća davanje kombinacije subjektu kojem je to potrebno.
13. Imetelstat natrij za uporabu prema patentnom zahtjevu 10, ABT-199 za uporabu prema patentnom zahtjevu 11 ili kombinacija za uporabu prema patentnom zahtjevu 12, pri čemu se imetelstat natrij primjenjuje tokom 1, 2, 3, 4, 5, 6, 7, 8 ili više od 8 ciklusa doziranja, pri čemu svaki ciklus doziranja sadrži:
(a) intravensku primjenu 7 - 10 mg/kg imetelstat natrija jednom u četiri tjedna;
(b) intravensku primjenu 7 - 10 mg/kg imetelstat natrija jednom tjedno tijekom četiri tjedna;
(c) intravensku primjenu 2.5 - 7 mg/kg imetelstat natrija jednom u tri tjedna; ili
(d) intravensku primjenu 0.5 - 9.4 mg/kg imetelstat natrija jednom svaka četiri tjedna.
14. Imetelstat natrij za uporabu prema patentnom zahtjevu 10, ABT-199 za uporabu prema patentnom zahtjevu 11 ili kombinacija za uporabu prema patentnom zahtjevu 12, pri čemu se ABT-199 primjenjuje u dozi od:
(a) 50 - 400 mg ABT-199 dnevno;
(b) 2 mg ABT-199 prvog dana sa dnevnom eskalacijom do konačne doze od 800 mg 6 dana i dnevno nakon toga; ili
(c) 25 mg ABT-199 prvog dana sa dnevnom eskalacijom do konačne doze od 400 mg 5 dana i dnevno nakon toga.
15. Imetelstat natrij za uporabu prema patentnom zahtjevu 10, ABT-199 za uporabu prema patentnom zahtjevu 11 ili kombinacija za uporabu prema patentnom zahtjevu 12, pri čemu se primjena ABT-199 vrši jedan dan prije, jedan dan poslije ili istog dana kada i primjena imetelstat natrija.
16. Komplet za uporabu u postupku liječenja akutne mijeloidne leukemije (AML), koji sadrži:
(a) imetelstat; i
(b) ABT-199 ili njegovu farmaceutski prihvatljivu sol.
17. Komplet prema patentnom zahtjevu 16, naznačen time da imetelstat je imetelstat natrij.
18. In vitro postupak za izazivanje apoptoze u stanici akutne mijeloidne leukemije (AML) koji se sastoji od:
dovođenje stanice u kontakt sa terapeutski efikasnom količinom imetelstat natrija; i dovođenje stanice u kontakt sa terapeutski efikasnom količinom ABT-199.
19. Farmaceutski pripravak koji sadrži imetelstat i ABT-199.
20. Farmaceutski pripravak prema patentnim zahtjevu 19, naznačen time da imetelstat je imetelstat natrij.
21. Farmaceutski pripravak prema patentnom zahtjevu 19, naznačen time što je pripravak za uporabu u liječenju akutne mijeloidne leukemije.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662370018P | 2016-08-02 | 2016-08-02 | |
| EP16197293.0A EP3318276A1 (en) | 2016-11-04 | 2016-11-04 | Combinations of a telomerase inhibitor and a bcl-2 inhibitor for the treatment of hematological cancers |
| US201662422738P | 2016-11-16 | 2016-11-16 | |
| EP17748613.1A EP3493812B1 (en) | 2016-08-02 | 2017-07-28 | Combinations of imetelstat and venetoclax for the treatment of acute myeloid leukaemia |
| PCT/US2017/044348 WO2018026646A1 (en) | 2016-08-02 | 2017-07-28 | Combination treatment for hematological cancers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20230300T1 true HRP20230300T1 (hr) | 2023-05-12 |
Family
ID=57226888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20230300TT HRP20230300T1 (hr) | 2016-08-02 | 2017-07-28 | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US11278561B2 (hr) |
| EP (3) | EP3318276A1 (hr) |
| JP (2) | JP7016856B2 (hr) |
| KR (2) | KR102515378B1 (hr) |
| CN (2) | CN109641002B (hr) |
| AU (2) | AU2017305950B2 (hr) |
| BR (1) | BR112019002025A2 (hr) |
| CA (2) | CA3032118C (hr) |
| CL (1) | CL2019000228A1 (hr) |
| DK (1) | DK3493812T3 (hr) |
| ES (1) | ES2941462T3 (hr) |
| FI (1) | FI3493812T3 (hr) |
| HR (1) | HRP20230300T1 (hr) |
| HU (1) | HUE061471T2 (hr) |
| IL (2) | IL305332A (hr) |
| LT (1) | LT3493812T (hr) |
| MA (1) | MA45845A (hr) |
| MD (1) | MD3493812T2 (hr) |
| MX (2) | MX2019001315A (hr) |
| NZ (1) | NZ750191A (hr) |
| PL (1) | PL3493812T3 (hr) |
| PT (1) | PT3493812T (hr) |
| RS (1) | RS64074B1 (hr) |
| SG (1) | SG11201900883UA (hr) |
| SI (1) | SI3493812T1 (hr) |
| WO (1) | WO2018026646A1 (hr) |
| ZA (1) | ZA201900939B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021510165A (ja) | 2018-01-10 | 2021-04-15 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | ベンズアミド化合物 |
| AU2020265225A1 (en) * | 2019-04-29 | 2021-10-28 | Immunogen, Inc. | Therapeutic combinations comprising anti-CD123 immunoconjugates |
| EP4281560A1 (en) * | 2021-01-22 | 2023-11-29 | The Regents of the University of California | Methods for treating and ameliorating cancer |
| CN114949230A (zh) * | 2022-06-13 | 2022-08-30 | 厦门大学附属第一医院 | 一种预防和/或治疗急性髓系白血病的联合用药物组合物及其应用 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5583016A (en) | 1994-07-07 | 1996-12-10 | Geron Corporation | Mammalian telomerase |
| US5958680A (en) | 1994-07-07 | 1999-09-28 | Geron Corporation | Mammalian telomerase |
| US5776679A (en) | 1994-07-07 | 1998-07-07 | Geron Corporation | Assays for the DNA component of human telomerase |
| KR20070112295A (ko) | 1999-09-10 | 2007-11-22 | 제론 코포레이션 | 올리고뉴클레오티드 엔3'→피5' 티오포스포라미데이트,이의 합성 및 용도 |
| KR101298493B1 (ko) | 2003-09-09 | 2013-08-21 | 제론 코포레이션 | 텔로머라제 억제를 위한 변형 올리고뉴클레오티드 |
| ATE553198T1 (de) | 2005-04-15 | 2012-04-15 | Geron Corp | Behandlung von krebs durch die kombinierte hemmung der proteasom- und telomeraseaktivitäten |
| WO2006113426A2 (en) | 2005-04-15 | 2006-10-26 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and tubulin activities |
| WO2006124904A2 (en) | 2005-05-16 | 2006-11-23 | Geron Corporation | Cancer treatment by combined inhibition of telomerase and hsp90 activities |
| HUE041448T2 (hu) | 2006-10-30 | 2019-05-28 | Geron Corp | Kombinált telomerázgátló és gemcitabin rák kezelésére |
| US8785409B2 (en) | 2007-01-30 | 2014-07-22 | Geron Corporation | Compounds having anti-adhesive effects on cancer cells |
| ES2407957T3 (es) | 2007-03-09 | 2013-06-17 | Geron Corporation | Tratamiento de carcinomas con una combinación de inhibidores de la vía EGF y de la telomerasa |
| EP2342360B1 (en) | 2008-10-17 | 2016-01-06 | Geron Corporation | Method for identification of sensitivity of a patient to telomerase inhibition therapy |
| WO2011017096A2 (en) * | 2009-08-04 | 2011-02-10 | Mayo Foundation For Medical Education And Research | Methods of treating hematologic cancers |
| JP2015536950A (ja) | 2012-11-02 | 2015-12-24 | ファーマサイクリックス，インク． | Ｔｅｃファミリーキナーゼ阻害剤アジュバント療法 |
| PT2925889T (pt) | 2012-11-30 | 2018-12-12 | Geron Corp | Marcadores de diagnóstico para o tratamento de transtornos da proliferação celular com inibidores da telomerase |
| US9200327B2 (en) | 2012-11-30 | 2015-12-01 | Geron Corporation | Diagnostic markers for treating cell proliferative disorders with telomerase inhibitors |
| US9375485B2 (en) | 2012-12-07 | 2016-06-28 | Geron Corporation | Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms |
| PT3456333T (pt) | 2012-12-07 | 2020-06-01 | Geron Corp | Utilização do inibidor de telomerase imetelstate para o tratamento de síndrome mielodisplásica |
| EA030957B1 (ru) | 2013-03-14 | 2018-10-31 | Оникс Терапьютикс, Инк. | Дипептидные и трипептидные эпоксикетонные ингибиторы протеазы |
| WO2014160071A1 (en) * | 2013-03-14 | 2014-10-02 | St. Jude Children's Research Hospital | Methods and compositions for the treatment of glutamine-addicted cancers |
| AU2014346840B2 (en) | 2013-11-06 | 2020-02-06 | Mayo Foundation For Medical Education And Research | Methods and materials for treating hematological malignancies |
| US11034757B2 (en) | 2014-06-09 | 2021-06-15 | Biomed Valley Discoveries, Inc. | Combination therapies using agents that target tumor-associated stroma or tumor cells and tumor vasculature |
| US9635050B2 (en) | 2014-07-23 | 2017-04-25 | Cisco Technology, Inc. | Distributed supervised architecture for traffic segregation under attack |
| US11486876B2 (en) | 2014-09-24 | 2022-11-01 | CeMM—FORSCHUNGSZENTRUM FÜR MOLEKULARE MEDIZIN GmbH | Monolayer of PBMCs or bone-marrow cells and uses thereof |
| WO2019023667A1 (en) | 2017-07-28 | 2019-01-31 | Janssen Biotech, Inc. | METHODS OF TREATING MYELODYSPLASTIC SYNDROME |
-
2016
- 2016-11-04 EP EP16197293.0A patent/EP3318276A1/en not_active Withdrawn
-
2017
- 2017-07-28 KR KR1020197005690A patent/KR102515378B1/ko active IP Right Grant
- 2017-07-28 HR HRP20230300TT patent/HRP20230300T1/hr unknown
- 2017-07-28 SI SI201731322T patent/SI3493812T1/sl unknown
- 2017-07-28 AU AU2017305950A patent/AU2017305950B2/en active Active
- 2017-07-28 PL PL17748613.1T patent/PL3493812T3/pl unknown
- 2017-07-28 EP EP17748613.1A patent/EP3493812B1/en active Active
- 2017-07-28 CA CA3032118A patent/CA3032118C/en active Active
- 2017-07-28 IL IL305332A patent/IL305332A/en unknown
- 2017-07-28 WO PCT/US2017/044348 patent/WO2018026646A1/en unknown
- 2017-07-28 CA CA3217021A patent/CA3217021A1/en active Pending
- 2017-07-28 MX MX2019001315A patent/MX2019001315A/es unknown
- 2017-07-28 DK DK17748613.1T patent/DK3493812T3/da active
- 2017-07-28 MA MA045845A patent/MA45845A/fr unknown
- 2017-07-28 NZ NZ750191A patent/NZ750191A/en unknown
- 2017-07-28 HU HUE17748613A patent/HUE061471T2/hu unknown
- 2017-07-28 KR KR1020237010185A patent/KR20230047206A/ko not_active Application Discontinuation
- 2017-07-28 JP JP2019504731A patent/JP7016856B2/ja active Active
- 2017-07-28 SG SG11201900883UA patent/SG11201900883UA/en unknown
- 2017-07-28 CN CN201780048256.1A patent/CN109641002B/zh active Active
- 2017-07-28 RS RS20230227A patent/RS64074B1/sr unknown
- 2017-07-28 ES ES17748613T patent/ES2941462T3/es active Active
- 2017-07-28 PT PT177486131T patent/PT3493812T/pt unknown
- 2017-07-28 IL IL264451A patent/IL264451B2/en unknown
- 2017-07-28 BR BR112019002025-0A patent/BR112019002025A2/pt active Search and Examination
- 2017-07-28 EP EP22216202.6A patent/EP4218768A1/en active Pending
- 2017-07-28 MD MDE20190665T patent/MD3493812T2/ro unknown
- 2017-07-28 LT LTEPPCT/US2017/044348T patent/LT3493812T/lt unknown
- 2017-07-28 FI FIEP17748613.1T patent/FI3493812T3/fi active
- 2017-07-28 CN CN202211230655.9A patent/CN116327954A/zh active Pending
- 2017-07-28 US US15/662,706 patent/US11278561B2/en active Active
-
2019
- 2019-01-29 CL CL2019000228A patent/CL2019000228A1/es unknown
- 2019-01-30 MX MX2022010466A patent/MX2022010466A/es unknown
- 2019-02-13 ZA ZA2019/00939A patent/ZA201900939B/en unknown
-
2022
- 2022-02-11 US US17/670,278 patent/US20220168333A1/en active Pending
- 2022-08-12 JP JP2022128782A patent/JP2022145948A/ja active Pending
-
2023
- 2023-09-15 AU AU2023229592A patent/AU2023229592A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20191957T1 (hr) | Policiklični-karbamoilpiridonski spojevi i njihova farmaceutska upotreba | |
| HRP20210902T1 (hr) | Postupci pojačavanja tonične inhibicije i liječenja angelmanovog sindroma | |
| HRP20230300T1 (hr) | Kombinacije imetelstata i venetoklaksa za liječenje akutne mijeloidne leukemije | |
| HRP20211543T1 (hr) | Derivati kinazolina koji se koriste za liječenje hiv-a | |
| MX2020008258A (es) | Formulaciones pediátricas de niraparib y métodos de tratamiento pediátricos. | |
| EA201590166A1 (ru) | Комбинированная терапия для лечения рассеянного склероза | |
| AR094374A1 (es) | Composiciones y métodos para el tratamiento de trastornos metabólicos | |
| HRP20230809T1 (hr) | Liječenje alzheimerove bolesti u određenoj populaciji bolesnika | |
| IL263110B (en) | Combined treatment of notch and pd-1 or pd-l1 inhibitors | |
| EA202090276A1 (ru) | Фармацевтическая композиция для лечения анемии | |
| MX2022015629A (es) | Uso de vibegron para tratar vejiga sobreactiva. | |
| BR112012030641A2 (pt) | métodos e composições para terapia farmacêutica oral | |
| RU2018107930A (ru) | Агонисты tlr4, их композиции и применение для лечения рака | |
| JP2016505050A5 (hr) | ||
| JP2017512194A5 (hr) | ||
| MY193963A (en) | Composition for treating joint diseases and kit containing same | |
| PH12018500817A1 (en) | Pharmaceutical composition comprising metformin and lobeglitazone | |
| JP2019529569A5 (hr) | ||
| EA201591653A1 (ru) | Композиции для лечения глазных расстройств с применением дипиридамола | |
| MX2018005298A (es) | Regimen de dosificacion para un inhibidor de fosfatidilinositol 3-quinasa. | |
| JP2017530142A5 (hr) | ||
| AR108792A1 (es) | Composiciones que comprenden timolol | |
| AR101227A1 (es) | Combinaciones de un derivado de n-tiazolil-4-fenoxibencenosulfonamida y un agente farmacéuticamente activo seleccionado a partir de gabapentina y pregabalina para tratar dolor | |
| EA201992816A1 (ru) | Фармацевтическая композиция и лекарственная форма, которая включает (e)-4-(2-(аминометил)-3-фтораллилокси)-n-трет-бутилбензамид, способ их приготовления, способы лечения и их применения | |
| EA201592261A1 (ru) | Фармацевтические композиции, включающие агомелатин в форме сокристаллов агомелатина с органической кислотой |